ALS (Amyotrophic Lateral Sclerosis) is a disease that affects motor neurons in the body causing deterioration of muscles. This video explores the role of motor neurons and other cells involved in the onset and progression of ALS.

[Please complete our feedback form]

  • Andrews, J. A., Miller, T. M., Vijayakumar, V., Stoltz, R., James, J. K., Meng, L., ... & Malik, F.I. (2018). CK‐2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve, 57(5), 729-734.
  • Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., ... & 1A complete listing of the BDNF Study Group. (1999). The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21.
  • ALS Association Golden West Chapter. Disease mechanisms. (n.d.).
  • Gothelf, Y., Kaspi, H., Abramov, N., & Aricha, R. (2017). miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors. Stem Cell Research & Therapy, 8(1), 249.
  • Kaji, R., Kodama, M., Imamura, A., Hashida, T., Kohara, N., Ishizu, M., ... & Kimura, J. (1998). Effect of ultrahigh‐dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double‐blind controlled study. Muscle & Nerve, 21(12), 1775-1778.
  • Paganoni, S., Cudkowicz, M., & Berry, J. D. (2014). Outcome measures in amyotrophic lateral sclerosis clinical trials. Clinical Investigation, 4(7), 605.
  • Shefner, J. M., & Gooch, C. L. (2003). Motor unit number estimation. Physical Medicine and Rehabilitation Clinics of North America, 14(2), 243-260.
  • Shiffman, C. A., Aaron, R., & Rutkove, S. B. (2015). U.S. Patent No. 9,014,797. Washington, DC: U.S. Patent and Trademark Office.
  • ALS Canada. Symptoms. (n.d.).
  • Van der Ploeg, R. J. O., Oosterhuis, H. J. G. H., & Reuvekamp, J. (1984). Measuring muscle strength. Journal of Neurology, 231(4), 200-203.
  • ALS Canada. What is ALS? (n.d.).